CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

Event · Earnings
Original reporting
Published Aug 6, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CTSO
Bullish
medium confidence
Mentioned
$CTSO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CTSOBullishMed
01

Why it matters

The most tradable elements are the quantified improvement in gross margin (to 73%), operating loss reduction (to $2.6M), and reduced operating cash burn (to about $200k excluding restructuring), alongside management’s stated expectation of operating cash flow breakeven in 2H 2026.

02

Market read

For CTSO, the filing shifts the near-term risk profile toward improved liquidity trajectory, while leaving regulatory timing and ongoing losses as key uncertainties.

03

What to watch

Germany revenue weakness is attributed to sales coverage, meaning the near-term rebound depends on hiring and territory restoration by early 2027, not just margin initiatives.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 6, 2026, for Q2 2026 results

Background

CytoSorbents filed an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and business/regulatory updates.

Company-level read

Ticker impact

$CTSOBullishMedium confidence
Context

CytoSorbents reported Q2 2026 results, including $9.6M revenue, 73% gross margin, and reduced operating cash burn to about $200k excluding restructuring.

Expected impact

Moderate positive bias for CTSO as traders focus on cash burn reduction and gross margin improvement, though losses and cash balance remain key overhangs.

Evidence & confidence

This is a primary SEC 8-K with quantified operating metrics (gross margin, operating loss, adjusted EBITDA loss, cash burn) and a management milestone claim (operating cash flow breakeven in 2H). However, the excerpt does not include full guidance or FDA decision timing, limiting conviction on forward earnings power.

Market effects

Signals incremental progress in commercialization and manufacturing efficiency for blood purification/ICU therapies, which can influence sentiment toward similar perioperative/critical-care medtech names.

Germany sales declined 24% due to a smaller sales force, highlighting execution risk in European markets for this franchise.

U.S. regulatory progress remains a key overhang, but the excerpt only frames the FDA approval objective rather than reporting a decision.

Counterpoint

Cash burn improved, but total cash fell to about $5.9M and the company still reported net loss, so the milestone may require additional financing or further execution to be credible.

Key entities

  • CytoSorbents Corporation

    NASDAQ-listed company reporting Q2 2026 financial results and providing regulatory and business execution updates.

  • Dr. Phillip Chan

    CEO quoted on revenue drivers, margin improvement, cash burn reduction, and hiring plans.

Related articles

$CTSOMed

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on the First of Four Distinct Value Drivers PRINCETON, N.J., November 12, 2026 — CytoSorbents Corporation (NASDAQ

$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.